Product Description
BEAM-201 is a highly differentiated editing program designed to provide an 'off-the-shelf' CD7-targeting CAR-T cell therapy that may enable a one-time treatment option for patients with T-ALL. To our knowledge, BEAM-201 is the first cell therapy featuring simultaneous edits to four genes. The preclinical data being presented at SITC 2020 demonstrate 96-99% editing efficiencies across four targets without genomic rearrangements, as well as strong in vivo proof of concept of tumor clearance in a xenograft model. We are actively advancing BEAM-201 to assess its potential impact in treating people living with this devastating disease. (Sourced from: https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-names-first-car-t-base-editing-development)
Mechanisms of Action: CAR-T, CD7
Novel Mechanism: Yes
Modality: Allogeneic CAR-T
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Beam Therapeutics
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Beam Therapeutics presented P1 Acute Lymphoid Leukemia results on 2024-12-09 for BEAM-201
- Clinical Outcomes Reported - Beam Therapeutics presented P1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia results on 2024-12-07 for BEAM-201
- Clinical Outcomes Reported - Beam Therapeutics announced they will present P1 T-Cell Lymphoma results in 2H24 for BEAM-201
Highest Development Phases
Phase 2: Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05885464 |
T-LL | P2 |
Active, not recruiting |
Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia|Lymphoid Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma |
2026-12-01 |
2025-08-27 |
Primary Endpoints|Treatments |